Related Experiment Video

Updated: Jul 13, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

The experience of beta-thalassaemia and its prevention in Cyprus

E M Kalokairinou1

  • 1Department of Classics and Philosophy of the University of Cyprus.

Medicine and Law
|July 21, 2007
PubMed

Insights

Beta-thalassaemia, a severe hereditary blood disorder, devastated Cyprus, nearly wiping out its population. A successful prevention and treatment program was implemented, demonstrating it was not eugenics.

Area of Science:

  • Medical Genetics
  • Public Health
  • Medical Ethics

Background:

  • Haemoglobinopathies are inherited blood disorders that are frequently fatal if untreated.
  • Beta-thalassaemia significantly impacted Cyprus, posing an existential threat to the population in the last century.

Purpose of the Study:

  • To examine the historical impact of beta-thalassaemia on Cyprus.
  • To analyze the ethical considerations faced by medical professionals, the state, and the church in addressing the beta-thalassaemia crisis.
  • To evaluate the success and ethical implications of the implemented treatment and prevention program.

Main Methods:

  • Historical case study analysis.
  • Review of medical records and public health initiatives.
  • Ethical framework analysis of decision-making processes.

Main Results:

  • Beta-thalassaemia posed a severe demographic threat to Cyprus.
  • A multifaceted program involving medical treatment and prevention was established.
  • The program successfully managed and reduced the incidence of beta-thalassaemia.

Conclusions:

  • The Cyprus beta-thalassaemia program, while successful in disease management, was distinct from eugenics.
  • The case highlights the complex interplay of medical, ethical, and societal factors in managing genetic diseases.
  • Effective public health strategies are crucial for controlling hereditary disorders.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...